⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27979265 | 0.84 | CA12 (0.52) | — | |
| SCHEMBL9555580 | 0.82 | — | — | |
| SCHEMBL96554 | 0.81 | — | — | |
| SCHEMBL8663660 | 0.81 | — | — | |
| SCHEMBL28929084 | 0.79 | ALDH1A1 (0.48) | — | |
| Ammonia Solution, Strong SCHEMBL28157014 | 0.78 | CA12 (0.48) | — | |
| SCHEMBL2115642 | 0.78 | — | — | |
| SCHEMBL9666762 | 0.78 | CA12 (0.59) | — | |
| SCHEMBL2830770 | 0.75 | — | — | |
| SCHEMBL1057984 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157247-A1 | ANTI-VIRAL THERAPY | Novabiotics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| US-11369568-B2 | Microparticles comprising a sulphur-containing compound | NOVABIOTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| WO-2021240145-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2021-12-02 | — | — | WO | disclosed |
| US-10905660-B2 | Microparticles | NOVABIOTICS LIMITED (GB) | 2021-02-02 | — | — | US | disclosed |
| US-20190175501-A1 | MICROPARTICLES COMPRISING A SULPHUR-ONTAINING COMPOUND | NOVABIOTICS LIMITED (GB) | 2019-06-13 | — | — | US | disclosed |
| EP-3463325-A1 | MICROPARTICLES COMPRISING A SULPHUR-CONTAINING COMPOUND | Novabiotics Limited (GB) | 2019-04-10 | — | — | EP | disclosed |
| EP-3307259-A1 | AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. | Novabiotics Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2017212249-A1 | MICROPARTICLES COMPRISING A SULPHUR-CONTAINING COMPOUND | NOVABIOTICS LIMITED (GB) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348254-A1 | MICROPARTICLES | NOVABIOTICS LIMITED (GB) | 2017-12-07 | — | — | US | disclosed |
| EP-3197476-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | Novabiotics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016198842-A1 | AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. | NOVABIOTICS LIMITED (GB) | 2016-12-15 | — | — | WO | disclosed |
| US-20160102052-A1 | Use of Cysteamine in Treating Infections caused by Yeasts/Moulds | NOVABIOTICS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| WO-2016046524-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | NOVABIOTICS LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |